Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA recommends excipients be used as physical chemical identifiers to thwart drug counterfeiters

This article was originally published in The Gold Sheet

Executive Summary

FDA has issued a draft guidance that recommends pharmaceutical manufacturers use "pharmacologically inactive" substances as physical-chemical identifiers (PCIDs) in solid oral dosage forms to fight drug counterfeiting. The draft guidance, entitled "Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting," notes that inks, pigments and flavors are some examples of substances that may be incorporated into solid dosage forms. The guidance notes that PCIDs should be "pharmacologically inactive so the ingredients can be treated as excipients." FDA recommends using "permissible direct food additives," including those affirmed as generally recognized as safe or those ingredients listed in the FDA Inactive Ingredient Guide to minimize toxicological risks. Various technologies that can be used to detect PCIDs include photolithography, holography, and laser scanning devices. The guide also addresses reporting or requesting approval to incorporate PCIDs into drug products as a postapproval change. Comments on the draft guidance are due Oct. 13

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel